Does transcatheter tricuspid valve intervention (TTVI) improve survival compared to medical therapy alone, and are there sex-related differences in outcomes for high-risk patients with tricuspid regurgitation?
TTVI provides a survival benefit over medical therapy alone in high-risk patients with tricuspid regurgitation, with similar short-term efficacy and clinical outcomes observed in both men and women.
After TTVI in high-risk patients, there were no sex-related differences in terms of survival, HF hospitalization, functional status, and TR reduction up to 1 year. The IPTW analysis shows a survival benefit of TTVI over medical therapy alone in both women and men.
Scotti et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: